FDA Approves new Boehringer COPD Drug

The US Food and Drug Administration (FDA) has approved German drugmaker Boehringer Ingelheim's Stiolto Respimat (tiotropium bromide and olodaterol) once-a-day inhalation spray for long-term treatment of chronic obstructive pulmonary disorder (COPD).

Boehringer's new product combines the active ingredients of its top-selling respiratory drug Spiriva with the active ingredient in Striverdi.

The German company said it expects the drug to be approved in Europe within the coming weeks. Affecting 210 million people worldwide, COPD is regarded as a growing world health priority and is predicted to become the third leading cause of death by 2030.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.